Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
LAMOTRIGINE
Profind Wholesale Ltd.
50 Milligram
Dispersable Tablet
2010-04-23
IRISH MEDICINES BOARD ACT 1995, AS AMENDED MEDICINAL PRODUCTS (CONTROL OF PLACING ON THE MARKET) REGULATIONS, 2007, AS AMENDED PPA1500/046/002 Case No: 2083758 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to PROFIND WHOLESALE LTD. UNIT 625, KILSHANE AVENUE, NORTHWEST BUSINESS PARK, DUBLIN 15, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product LAMICTAL 50MG DISPERSIBLE/CHEWABLE TABLETS the particulars of which are set out in the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 28/07/2010. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 28/07/2010_ _CRN 2083758_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lamictal 50mg dispersible/chewable Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each dispersible/chewable tablet contains 50mg lamotrigine. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Dispersible/chewable tablet _Product imported from France:_ White to off white square tablet with rounded corners marked ‘GSCX7’ on one side and ‘50’ on the other. The tablets have a blackcurrant odour and may be slightly mottled. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Epilepsy _Adults and adolescents aged 13 years and above_ - Adjunctive or monotherapy treatment of partial seizures and genera Preberite celoten dokument